The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
Background: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostate cancers (PCa), and the curative effect of anti-PD-1...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.01494/full |
| _version_ | 1818650771323879424 |
|---|---|
| author | Yan Li Yan Li Qingying Huang Yaoyao Zhou Meizhi He Jianhong Chen Yubo Gao Xue Wang |
| author_facet | Yan Li Yan Li Qingying Huang Yaoyao Zhou Meizhi He Jianhong Chen Yubo Gao Xue Wang |
| author_sort | Yan Li |
| collection | DOAJ |
| description | Background: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostate cancers (PCa), and the curative effect of anti-PD-1/PD-L1 therapy remains controversial. In this systematic review and meta-analysis, we aimed to evaluate the prognostic and clinicopathologic value of PD-L1 in PCa.Methods: We performed a systematic literature search in the PubMed, Cochrane Library, EMBASE, Web of Science, and SCOPUS databases up to July 21st, 2018. Pooled prevalence of PD-L1 in PCa was calculated using Freeman-Tukey double arcsine transformation by R software version 3.5.0. The data from the studies were examined by a meta-analysis using Review Manager software 5.3 to calculate pooled hazard ratios (HRs) and pooled odds ratios (ORs) with 95% confidence intervals (CIs) to estimate the prognostic and clinicopathologic value of PD-L1 in PCa. Heterogeneity was tested by the Chi-squared test and I2 statistic.Results: Five studies with 2,272 patients were included in this meta-analysis. The pooled prevalence of PD-L1 in PCa was 35% (95% CI 0.32 to 0.37). Both PD-L1 expression (HR = 1.78; 95% CI 1.39 to 2.27; p < 0.00001) and PD-L1 DNA methylation (HR = 2.23; 95% CI 1.51 to 3.29; p < 0.0001) were significantly associated with poor biochemical recurrence-free survival (BCR-FS). PD-L1 tended to have high expression levels in high Gleason score cases (OR = 1.54; 95% CI, 1.17 to 2.03; P = 0.002) and androgen receptor-positive cases (OR = 2.42, 95% CI 1.31 to 4.50; P = 0.005). However, PD-L1 had relatively weak correlation with age, pathologic stage, lymph node metastasis and preoperative PSA level.Conclusions: This meta-analysis confirms the negative prognostic significance of PD-L1 expression and mPD-L1 in PCa patients. Additionally, PD-L1 has a statistically significant correlation with Gleason score and androgen receptor status, while the correlations with age, pathologic stage, lymph node metastasis, and preoperative PSA level were not statistically significant. However, the number of included studies is too small to make the conclusions more convincing, so more retrospective large-cohort studies are expected for the further confirmation of these findings. |
| first_indexed | 2024-12-17T01:55:31Z |
| format | Article |
| id | doaj.art-33b5113bb48a48ec91fde88212f81e7c |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-17T01:55:31Z |
| publishDate | 2019-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-33b5113bb48a48ec91fde88212f81e7c2022-12-21T22:07:59ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-01-01910.3389/fphar.2018.01494425203The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-AnalysisYan Li0Yan Li1Qingying Huang2Yaoyao Zhou3Meizhi He4Jianhong Chen5Yubo Gao6Xue Wang7Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, ChinaDepartment of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Plastic and Cosmetic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaBackground: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostate cancers (PCa), and the curative effect of anti-PD-1/PD-L1 therapy remains controversial. In this systematic review and meta-analysis, we aimed to evaluate the prognostic and clinicopathologic value of PD-L1 in PCa.Methods: We performed a systematic literature search in the PubMed, Cochrane Library, EMBASE, Web of Science, and SCOPUS databases up to July 21st, 2018. Pooled prevalence of PD-L1 in PCa was calculated using Freeman-Tukey double arcsine transformation by R software version 3.5.0. The data from the studies were examined by a meta-analysis using Review Manager software 5.3 to calculate pooled hazard ratios (HRs) and pooled odds ratios (ORs) with 95% confidence intervals (CIs) to estimate the prognostic and clinicopathologic value of PD-L1 in PCa. Heterogeneity was tested by the Chi-squared test and I2 statistic.Results: Five studies with 2,272 patients were included in this meta-analysis. The pooled prevalence of PD-L1 in PCa was 35% (95% CI 0.32 to 0.37). Both PD-L1 expression (HR = 1.78; 95% CI 1.39 to 2.27; p < 0.00001) and PD-L1 DNA methylation (HR = 2.23; 95% CI 1.51 to 3.29; p < 0.0001) were significantly associated with poor biochemical recurrence-free survival (BCR-FS). PD-L1 tended to have high expression levels in high Gleason score cases (OR = 1.54; 95% CI, 1.17 to 2.03; P = 0.002) and androgen receptor-positive cases (OR = 2.42, 95% CI 1.31 to 4.50; P = 0.005). However, PD-L1 had relatively weak correlation with age, pathologic stage, lymph node metastasis and preoperative PSA level.Conclusions: This meta-analysis confirms the negative prognostic significance of PD-L1 expression and mPD-L1 in PCa patients. Additionally, PD-L1 has a statistically significant correlation with Gleason score and androgen receptor status, while the correlations with age, pathologic stage, lymph node metastasis, and preoperative PSA level were not statistically significant. However, the number of included studies is too small to make the conclusions more convincing, so more retrospective large-cohort studies are expected for the further confirmation of these findings.https://www.frontiersin.org/article/10.3389/fphar.2018.01494/fullprostate cancerPD-1/PD-L1prognosticclinicopathologicmeta-analysis |
| spellingShingle | Yan Li Yan Li Qingying Huang Yaoyao Zhou Meizhi He Jianhong Chen Yubo Gao Xue Wang The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis Frontiers in Pharmacology prostate cancer PD-1/PD-L1 prognostic clinicopathologic meta-analysis |
| title | The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
| title_full | The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
| title_fullStr | The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
| title_short | The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis |
| title_sort | clinicopathologic and prognostic significance of programmed cell death ligand 1 pd l1 expression in patients with prostate cancer a systematic review and meta analysis |
| topic | prostate cancer PD-1/PD-L1 prognostic clinicopathologic meta-analysis |
| url | https://www.frontiersin.org/article/10.3389/fphar.2018.01494/full |
| work_keys_str_mv | AT yanli theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT yanli theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT qingyinghuang theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT yaoyaozhou theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT meizhihe theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT jianhongchen theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT yubogao theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT xuewang theclinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT yanli clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT yanli clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT qingyinghuang clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT yaoyaozhou clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT meizhihe clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT jianhongchen clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT yubogao clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis AT xuewang clinicopathologicandprognosticsignificanceofprogrammedcelldeathligand1pdl1expressioninpatientswithprostatecancerasystematicreviewandmetaanalysis |